-
2023-508280-69-00
1
2022-10-07
Advanced Malignant Tumors
-
2023-505458-16-00
5
2022-09-13
Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpressio
-
2024-511750-53-00
7
2022-09-08
Unresectable Locally Advanced or Metastatic Cancer
-
2023-504257-12-00
4
2022-07-28
Portal hypertension
-
2023-505005-16-00
4
2022-07-27
Primary peritoneal cancer/Fallopian tube cancer
-
2024-513559-34-00
5
2022-07-19
Small Cell Lung Cancer (SCLC)
-
2023-505455-44-00
9
2022-06-29
Solid tumours
-
2024-512007-39-00
4
2022-06-20
Chronic Obstructive Pulmonary Disease
-
2023-504363-17-00
7
2022-05-13
Advanced MTAP-null solid tumors
-
2022-502802-34-00
5
2022-04-05
Dravet and Lennox-Gastaut Syndromes
-
2023-506310-43-00
1
2022-02-15
BRAF-V600 Mutation-Positive Advanced Solid Tumor or BRAF-V600 Mutation
-
2023-505457-40-00
5
2022-02-02
Previously Untreated Advanced Gastric or Gastroesophageal Junction
Can
-
2023-507093-40-00
4
2022-01-27
Chronic Obstructive Pulmonary Disease (COPD)
-
2023-509406-30-00
10
2022-01-24
Patients with HER2-overexpressing advanced or metastatic gastric or ga
-
2023-509018-12-00
5
2021-12-17
Moderately to severely active Ulcerative Colitis (UC)
-
2024-510722-10-00
7
2021-12-13
Malignant Solid Tumors
-
2024-510762-16-00
4
2021-11-30
Metastatic head and neck squamous cell carcinoma (HNSCC)
-
2024-515295-12-00
4
2021-10-06
High-grade glioma (HGG)
-
2024-514326-23-00
11
2021-09-10
Crohn's disease
-
2023-510046-25-00
7
2021-09-02
Soild Tumors
-
2023-506961-74-00
4
2021-08-31
Non-alcoholic steatohepatitis (NASH)
-
2023-503905-12-00
4
2021-08-20
Liver cancer; Colon cancer; Pancreatic cancer; Bile Duct or Gallbladde
-
2024-512805-18-00
3
2021-08-03
solid tumour harbouring G12C mutation
-
2024-511481-37-00
4
2021-07-12
Previously Treated, Locally-Advanced Unresectable or Metastatic Solid